Moloney Securities Asset Management LLC Has $1.21 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Moloney Securities Asset Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 78.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,458 shares of the company's stock after acquiring an additional 7,661 shares during the quarter. Moloney Securities Asset Management LLC's holdings in Novo Nordisk A/S were worth $1,212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in NVO. Bank of America Corp DE boosted its position in Novo Nordisk A/S by 8.1% during the 4th quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock worth $1,332,655,000 after acquiring an additional 1,165,955 shares during the period. GQG Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after buying an additional 5,556,460 shares during the period. Loomis Sayles & Co. L P lifted its holdings in shares of Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Novo Nordisk A/S by 1.5% during the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock valued at $715,084,000 after purchasing an additional 123,681 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in shares of Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 2.9%

Shares of NYSE NVO traded down $2.08 during mid-day trading on Friday, reaching $68.93. 6,511,310 shares of the company traded hands, compared to its average volume of 7,316,084. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The stock has a market cap of $307.77 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64. The company's fifty day moving average is $70.35 and its two-hundred day moving average is $75.08. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $143.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on NVO shares. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Finally, Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.